Company intelligence / Profile preview

Genmedica Therapeutics

Barcelona / Esplugues de Llobregat*, Catalonia, Spainpmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Phase 2

Overview

Genmedica Therapeutics develops novel oral therapies for type 2 diabetes. Its lead candidate, GMC252, combines anti-inflammatory and antioxidant properties in a single small molecule. The compound has demonstrated efficacy in animal models and an excellent safety profile in Phase I trials; it advanced to Phase IIa proof-of-concept studies as of the latest available updates. The company has raised significant venture funding to support these efforts.

Therapeutic areas: EndocrinologyMetabolic Disorders
Modalities: Small molecules
Industry: Biotech

Drug pipeline

2 assets

GMC-316

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Asclepios Bioresearch (major investor/funding partner)

Beyond the preview

Go deeper on Genmedica Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genmedica Therapeutics.

Explore the full profile